M701

Phase 3Small molecule

WWuhan YZY Biopharma Co., Ltd.

M701 is one of 2 small molecule programs targeting Malignant Ascites. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant AscitesActive, not recruiting

Malignant AscitesPhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Malignant Ascites

#DrugCompanyPhaseTrials

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Phase 2

1 2

M701

WWuhan YZY Biopharma Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Malignant Ascites

NCT06432296

PreclinicalRecruiting

Malignant Pleural Effusions

NCT05543330

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Completed·WWuhan YZY Biopharma Co., Ltd.·Phase 2·NCT06266091·115 enrolled

Malignant Ascites1 trial

A Randomized, Controlled, Multi-Center Phase III Clinical Study to Evaluate the Efficacy and Safety of M701 for Intraperitoneal Injection in Patients With Malignant Ascites Caused by Advanced Epithelial Solid Tumors

Active, not recruiting·WWuhan YZY Biopharma Co., Ltd.·Phase 3·NCT06432296·312 enrolled

Malignant Pleural Effusions1 trial

A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of M701, a Recombinant Epcam and CD3 Bispecific Antibody , in Patients With Malignant Pleural Effusions Caused by NSCLC

Recruiting·WWuhan YZY Biopharma Co., Ltd.·Preclinical·NCT05543330·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for M701. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — M701 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for M701. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wuhan YZY Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWuhan YZY Biopharma Co., Ltd.

M701

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ovarian Cancer1 trial

Malignant Ascites1 trial

Malignant Pleural Effusions1 trial

References

Drug Info

Quick Facts

Related News